Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Entheon Biomedical Corp. is a clinical-stage biotechnology company that was focused on developing psychedelic-assisted therapies, primarily for substance use disorders. The company operated within the biotechnology and mental health therapeutics industries, with an emphasis on addiction treatment using regulated psychedelic compounds. Its core strategy centered on the medical development of DMT-based therapeutics delivered in controlled clinical settings.
Entheon was incorporated in Canada and became publicly traded on the OTC Markets under the ticker ENBIX. The company’s primary target market consisted of patients with opioid, alcohol, and other substance use disorders, as well as clinical providers and research institutions specializing in addiction medicine. Entheon positioned itself around the potential advantages of short-acting psychedelic compounds, which it argued could reduce treatment time and cost compared to longer-duration psychedelics. The company was founded in 2020 and pursued early-stage clinical and preclinical development before entering creditor protection proceedings in 2023, after which active operations were significantly curtailed.
Business Operations
Entheon’s business operations were centered on a single primary operating segment: psychedelic-derived addiction therapeutics research and development. The company did not generate commercial revenue and operated as a pre-revenue clinical-stage issuer. Its activities included drug formulation research, intellectual property development, regulatory planning, and preparation for clinical trials related to DMT-assisted therapy protocols.
Operations were conducted through its wholly owned subsidiary Entheon Pharma Corp., which held the company’s drug development assets and intellectual property. Entheon did not report material international commercial operations or manufacturing assets and relied on third-party research organizations and academic collaborations for aspects of development. Public disclosures indicate no material joint ventures or revenue-producing partnerships prior to the company’s insolvency proceedings. Data inconclusive based on available public sources regarding the current status of any remaining operating assets.
Strategic Position & Investments
Strategically, Entheon sought to differentiate itself within the psychedelic medicine sector by focusing on DMT, a compound characterized by a short psychoactive duration, which management believed could improve scalability and clinical efficiency. Growth initiatives were primarily limited to advancing preclinical research, securing intellectual property, and preparing for regulatory engagement rather than commercial expansion.
The company made limited investments relative to larger peers and did not complete any significant acquisitions. Its most notable corporate action was the earlier spin-out of genetic testing assets into HaluGen Life Sciences Inc., which became an independent entity. Following its filing under the Companies’ Creditors Arrangement Act (CCAA) in Canada, Entheon entered a restructuring process, and available public disclosures indicate that strategic development activities were suspended. Data inconclusive based on available public sources regarding post-restructuring ownership of specific assets.
Geographic Footprint
Entheon was headquartered in Canada, with corporate offices historically reported in Vancouver, British Columbia. Its operational footprint was limited, with activities primarily concentrated in North America. The company did not report established commercial operations in Europe, Asia-Pacific, or other international markets.
International exposure was largely indirect, consisting of scientific research awareness and participation in the broader global psychedelic research ecosystem rather than physical operations or investments. There is no verified public information indicating ongoing international subsidiaries or active foreign operations following the company’s creditor protection filing.
Leadership & Governance
Entheon was founded by entrepreneurs with backgrounds in biotechnology and alternative therapeutics. Its leadership emphasized an evidence-based approach to psychedelic medicine, with a stated focus on regulatory compliance, clinical rigor, and physician-led treatment models. Governance followed standard public-company structures prior to insolvency proceedings.
Key executives publicly associated with the company included:
- Timothy Ko – Chief Executive Officer
- Russell Potter – Chairman of the Board
- John Fraser – Chief Financial Officer
- Dr. Russell Kennedy – Scientific Advisor
Following the initiation of creditor protection proceedings, the extent to which this leadership structure remains intact is unclear. Data inconclusive based on available public sources regarding current executive roles or board composition.